复星医药控股子公司HLX37注射液获临床试验批准

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotech Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of HLX37, a dual-specific antibody injection for treating advanced/metastatic solid tumors [1] Group 1: Company Developments - The approved product, HLX37, is a recombinant humanized anti-PD-L1 and anti-VEGF dual-specific antibody injection [1] - The company plans to conduct Phase I clinical trials for HLX37 in China once conditions are met [1] - Preclinical studies indicate that HLX37 can inhibit tumor growth and has good safety profiles [1]